Literature DB >> 7685391

Analysis of the interactions of HIV1 replication primer tRNA(Lys,3) with nucleocapsid protein and reverse transcriptase.

C Barat1, O Schatz, S Le Grice, J L Darlix.   

Abstract

Packaging of the genomic RNA dimer and replication primer tRNA(Lys,3) into HIV virions are required for the production of infectious virus. The initiation of reverse transcription necessitates the annealing of tRNA(Lys,3) to the primer binding site (PBS) of HIV RNA by nucleocapsid (NC) protein. In this report the interactions of replication primer tRNA(Lys,3) with various forms of reverse transcriptase (RT) and nucleocapsid protein have been analyzed by ultraviolet light (UV) cross-linking and gel retardation assays. We show that of the three forms of RT studied, p66/p51, p66 and p51, only the heterodimer p66/p51 can tightly and stably interact with tRNA(Lys,3). Tight interactions between tRNA(Lys,3) and nucleocapsid protein, either NCp15 or NCp7, were found to take place within the anticodon domain. Interestingly enough, primer tRNA(Lys,3) can interact with RTp66/p51 and NCp15 to form a high molecular weight complex in which RTp66/p51 appears to enhance the binding of NCp15 to tRNA(Lys,3). These findings favor the notion that the RT enzyme and NC protein co-operate to select and package primer tRNA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685391     DOI: 10.1006/jmbi.1993.1273

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  38 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

3.  Multiple molecular determinants for retrotransposition in a primer tRNA.

Authors:  J B Keeney; K B Chapman; V Lauermann; D F Voytas; S U Aström; U von Pawel-Rammingen; A Byström; J D Boeke
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

4.  Mutated primer binding sites interacting with different tRNAs allow efficient murine leukemia virus replication.

Authors:  A H Lund; M Duch; J Lovmand; P Jørgensen; F S Pedersen
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA.

Authors:  L Rong; C Liang; M Hsu; L Kleiman; P Petitjean; H de Rocquigny; B P Roques; M A Wainberg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).

Authors:  J K Wakefield; A G Wolf; C D Morrow
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Solution structure and backbone dynamics of Mason-Pfizer monkey virus (MPMV) nucleocapsid protein.

Authors:  Y Gao; K Kaluarachchi; D P Giedroc
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

8.  The yeast Ty3 retrotransposon contains a 5'-3' bipartite primer-binding site and encodes nucleocapsid protein NCp9 functionally homologous to HIV-1 NCp7.

Authors:  C Gabus; D Ficheux; M Rau; G Keith; S Sandmeyer; J L Darlix
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

9.  A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  D Harrich; C Ulich; R B Gaynor
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  C Ulich; A Dunne; E Parry; C W Hooker; R B Gaynor; D Harrich
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.